Could a common supplement supercharge cancer immunotherapy?

NCT ID NCT07161310

Recruiting now Symptom relief Sponsor: Goethe University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A or a placebo alongside their first-line immunotherapy. The main goal is to see if the supplement changes the types of immune cells in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Urolithin A (a dietary supplement)
What this could lead to: If it works, this could point toward a way to enhance the effectiveness of immunotherapy for solid tumors like lung cancer and melanoma.
What could go wrong: This is a very early, small trial (45 people) focused on immune system changes, not on curing cancer. The supplement may have no effect or could interact with treatments in unexpected ways.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA NON-SMALL CELL LUNG CANCER SOLID CANCER

Contacts and locations

Locations

Universitätsklinikum Frankfurt, Medizinische Klinik II, Hämatologie/Onkologie
RECRUITING

Frankfurt, 60590, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.